BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 252 filers reported holding BIO-TECHNE CORP in Q1 2016. The put-call ratio across all filers is - and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $143,802 | +17.5% | 2,007 | +15.4% | 0.02% | +13.3% |
Q1 2024 | $122,409 | +2732.9% | 1,739 | +3005.4% | 0.02% | +1400.0% |
Q4 2023 | $4,321 | -96.2% | 56 | -96.7% | 0.00% | -94.1% |
Q3 2023 | $114,630 | -16.6% | 1,684 | 0.0% | 0.02% | -5.6% |
Q2 2023 | $137,465 | +32.3% | 1,684 | +20.3% | 0.02% | +28.6% |
Q1 2023 | $103,866 | +18.0% | 1,400 | +351.6% | 0.01% | -6.7% |
Q3 2022 | $88,000 | -17.8% | 310 | 0.0% | 0.02% | -16.7% |
Q2 2022 | $107,000 | -38.2% | 310 | -22.5% | 0.02% | -28.0% |
Q1 2022 | $173,000 | -16.4% | 400 | 0.0% | 0.02% | -7.4% |
Q4 2021 | $207,000 | +20.3% | 400 | +12.7% | 0.03% | +12.5% |
Q3 2021 | $172,000 | +5633.3% | 355 | +5816.7% | 0.02% | – |
Q2 2021 | $3,000 | +200.0% | 6 | +100.0% | 0.00% | – |
Q4 2020 | $1,000 | -98.5% | 3 | -99.6% | 0.00% | -100.0% |
Q4 2015 | $68,000 | -1.4% | 750 | 0.0% | 0.01% | -16.7% |
Q3 2015 | $69,000 | +115.6% | 750 | +114.3% | 0.01% | +200.0% |
Q4 2014 | $32,000 | – | 350 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 54,711 | $28,304,000 | 8.66% |
Montanaro Asset Management Ltd | 104,450 | $54,036,000 | 5.45% |
Ownership Capital B.V. | 891,186 | $461,046,000 | 4.99% |
Sandhill Capital Partners LLC | 121,682 | $62,951,000 | 4.89% |
Brown Capital Management | 986,803 | $510,513,000 | 4.22% |
STONE RUN CAPITAL, LLC | 22,300 | $11,536,000 | 3.73% |
DF DENT & CO INC | 681,416 | $352,524,000 | 3.54% |
MAIRS & POWER INC | 653,815 | $338,244,000 | 3.13% |
Summit Creek Advisors LLC | 57,959 | $29,985,000 | 3.01% |
Aristotle Atlantic Partners, LLC | 95,597 | $49,456,000 | 2.87% |